✦ LIBER ✦

A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer

✍ Scribed by Robert M. Silgals; James D. Ahlgren; John R. Neefe; John Rothman; Seth Rudnick; F. Peter Galicky; Philip S. Schein

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 473 KB
Volume: 54
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19841115)54:10<2257::aid-cncr2820541032>3.0.co;2-c

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Continuous infusion of high-dose 5-fluor

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A multicenter phase II study

✍ Cornelis J. A. Punt; Jos Th. M. Burghouts; Jelle J. Croles; Peter A. van Liessum 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

A Phase II trial of high dose epirubicin

A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma

✍ Kathy D. Miller; Nikhil Munshi; David Loesch; Lawrence H. Einhorn; George W. Sle 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when adminis

A phase II study of recombinant human al

A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer

✍ Carol M. Van Haelst-Pisani; Ronald L. Richardson; John Su; Jan C. Buckner; Richa 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 2 views

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas

A phase II trial of 5-fluorouracil, leuc

A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas

✍ Werner Scheithauer; Franz Pfeffel; Gabriela Kornek; Arthur Marczell; Christoph W 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 301 KB 👁 2 views

Bimonthly high dose leucovorin and 5-flu

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma

✍ Christophe Tournigand; Christophe Louvet; Aimery de Gramont; Elisabeth Lucchi; J 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

disease progression. IFN was administered subcutaneously three times weekly at for the Groupe d'Etude et de a dose of 3 MU (body surface area [BSA] õ 1.75 m 2 ) or 4.5 MU (BSA ¢ 1.75 m 2 ). Recherche sur les Cancers de RESULTS. World Health Organization toxicity Grade 3-4 occurred in 21 patients l'O